or Try an Advanced Search...

    Morphinans Stocks List

    Symbol Grade Name % Change
    NKTR B Nektar Therapeutics -5.99
    COLL C Collegium Pharmaceutical, Inc. 0.00
    TRVI C Trevi Therapeutics, Inc. 0.33
    DRRX D DURECT Corporation 17.17
    INDV F Indivior PLC 0.11
    ALKS F Alkermes plc 0.80
    PMD F Psychemedics Corporation -3.27
    TTNP F Titan Pharmaceuticals, Inc. 2.69
    VRPX F Virpax Pharmaceuticals, Inc. 0.45
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Opioids Chemical Compounds Euphoriants Organic Compounds Pain Pharmaceutical Schizophrenia Biopharmaceutical Chronic Pain Drug Delivery Drugs Ethers Hydrocodone Hyperactivity Disorder Oxycodone Phenols Analgesics Attention Deficit Hyperactivity Disorder Atypical Antipsychotics Bupivacaine

    Related ETFs - A few ETFs which own one or more of the above listed Morphinans stocks.

    Symbol Grade Name Weight
    PSIL F AdvisorShares Psychedelics ETF 4.75
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 4.66
    IBRN D iShares Neuroscience and Healthcare ETF 3.61
    FBT D First Trust Amex Biotech Index Fund 3.29
    PBE C PowerShares Dynamic Biotech & Genome 3.21
    View all Morphinans ETFs...
    Compare ETFs
    Compare PSCH to FBT Compare PSIL to IBRN Compare PSIL to PBE

        Morphinans Stocks Recent News

        Date Stock Title
        May 2 NKTR Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
        May 2 ALKS Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
        May 2 COLL Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
        May 2 ALKS Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
        May 1 TRVI Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
        May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
        May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
        May 1 ALKS Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 ALKS Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
        May 1 ALKS Alkermes Non-GAAP EPS of $0.43 misses by $0.15, revenue of $350.4M misses by $9.87M
        May 1 ALKS Alkermes plc Reports First Quarter 2024 Financial Results
        Apr 30 ALKS Alkermes Q1 2024 Earnings Preview
        Apr 30 ALKS How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
        Apr 30 DRRX DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
        Apr 29 COLL Collegium enters authorized generic agreement with Hikma for Nucynta franchise
        Apr 29 COLL Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
        Apr 29 COLL Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Opioids Chemical Compounds Euphoriants Organic Compounds Pain Pharmaceutical Schizophrenia Biopharmaceutical Chronic Pain Drug Delivery Drugs Ethers Hydrocodone Hyperactivity Disorder Oxycodone Phenols Analgesics Attention Deficit Hyperactivity Disorder Atypical Antipsychotics Bupivacaine
        Morphinans

        Morphinan is the prototype chemical structure of a large chemical class of psychoactive drugs, consisting of opiate analgesics, cough suppressants, and dissociative hallucinogens, among others.

        More about Morphinans
        Browse All Tags